Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8901 results

  1. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  2. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  3. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  4. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    In development Reference number: GID-TA11440 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  7. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  9. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  10. Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    Awaiting development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    Awaiting development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development